Plus Therapeutics

Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference

Retrieved on: 
Dienstag, August 8, 2023
Society, Plus Therapeutics, University of Texas at Austin, Plus, Hematology, SNO, CNS, Associate, Central nervous system, ASCO, Gareth Jones (researcher), University, Pakistan Society of Neuro-Oncology, PSTV, Webcast, Neurology, Neurosurgery, Rhenium, Research, Therapy, Conference, Safety, Northwestern, Pharmaceutical industry, Medicine

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced a key opinion leader roundtable discussion to be held on Friday, August 11, 2023, 8:00 a.m. – 9:00 a.m. ET to discuss the latest data from the ReSPECT-LM clinical trial of rhenium (186Re) obisbemeda that will be presented at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference on August 10, 2023.

Key Points: 
  • ET to discuss the latest data from the ReSPECT-LM clinical trial of rhenium (186Re) obisbemeda that will be presented at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference on August 10, 2023.
  • The webinar will feature a comprehensive discussion about the ongoing ReSPECT-LM Phase 1/2a dose escalation clinical trial, including key safety, tolerability, dosing, feasibility and efficacy data.
  • Justin Walsh, Ph.D., Senior Healthcare Analyst, Jones Research will moderate the roundtable and in addition will provide an overview of the radiotherapeutic market.
  • The webcast will be available on the Company’s website for 90 days following the live call.

Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Retrieved on: 
Donnerstag, August 3, 2023
Plus, PSTV, Canaccord Genuity, Therapy, Conference, Plus Therapeutics, Pharmaceutical industry

AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to present at the Canaccord Genuity 43rd Annual Growth Conference, on Wednesday, August 9, 2023 at 8:00 a.m.

Key Points: 
  • AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to present at the Canaccord Genuity 43rd Annual Growth Conference, on Wednesday, August 9, 2023 at 8:00 a.m.
  • ET at the InterContinental Boston in Boston, Mass.
  • Investors interested in arranging a meeting with the Company’s management during the conference should contact the Canaccord Genuity conference coordinator.
  • A webcast of the presentation can be found under the For Investors tab of the Plus website at www.plustherapeutics.com .

Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations

Retrieved on: 
Donnerstag, Juli 27, 2023
Triple-negative breast cancer, PTC Therapeutics, Central nervous system, University, Plus Therapeutics, Clinical trial, Drug, Lung cancer, Glioblastoma, Rashtrasant Tukadoji Maharaj Nagpur University, Immunomedics, Patient, PSTV, PLUS, FDA, Therapy, Breast cancer, Pharmaceutical industry

Pharm., Ph.D., as Vice President of Clinical Operations.

Key Points: 
  • Pharm., Ph.D., as Vice President of Clinical Operations.
  • Dr. Maliakal will be responsible for the strategy and planning of key clinical operational initiatives, focusing on advancing the Company’s lead clinical trials, ReSPECT-GBM and ReSPECT-LM, and further developing the broader pipeline.
  • Dr. Maliakal is an accomplished R&D professional who brings over 20 years of global and domestic experience to Plus Therapeutics.
  • Prior to joining the Company, he served as Director of Clinical Science at PTC Therapeutics, leading the clinical development, clinical trial operations, strategies, and data interpretations of all oncology assets across the enterprise.

Plus Therapeutics to Present at the 2023 SNO/ASCO CNS Cancer Conference

Retrieved on: 
Donnerstag, Juli 27, 2023
Society, Safety, SNO, Plus Therapeutics, CNS, Central nervous system, ASCO, Convection, Pakistan Society of Neuro-Oncology, HGG, CED, LM, PSTV, Decompression (diving), Therapy, Conference, Pharmaceutical industry, Rhenium

AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will share three poster presentations at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference taking place August 10-12, 2023 in San Francisco, California.

Key Points: 
  • AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will share three poster presentations at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) Cancer Conference taking place August 10-12, 2023 in San Francisco, California.
  • All presentations will be showcased during the Poster Reception on Thursday, August 10, 2023, beginning at 5:30 p.m. PT/8:30 p.m.
  • ET.
  • [TIPS-23] Safety and Feasibility Results from a Phase 1/2 Clinical Trial of Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioma: The ReSPECT-GBM Trial
    [TIPS-22] A two-part, Phase 1 study of Rhenium (186Re) Obisbemeda (186RNL) delivered by convection enhanced delivery (CED) for recurrent, refractory, or progressive childhood ependymoma and high-grade glioma (HGG)

Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit

Retrieved on: 
Donnerstag, Juli 13, 2023
Trial of the century, PSTV, Decompression (diving), Future, Radiopharmaceutical, Rhenium, Therapy, Plus Therapeutics, Pharmaceutical industry, Medical imaging

AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer, will give two presentations at the Targeted Radiopharmaceuticals Summit taking place July 25-27, 2023 in Boston, Massachusetts.

Key Points: 
  • AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer, will give two presentations at the Targeted Radiopharmaceuticals Summit taking place July 25-27, 2023 in Boston, Massachusetts.
  • The presentations will describe data from the ReSPECT-GBM clinical study evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (rGBM), as well as provide an overview of the Company’s scientific approach, current pipeline and a snapshot of where it is headed.
  • Targeted Radiopharmaceuticals in the US: The Past, the Present & the Future

Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting

Retrieved on: 
Donnerstag, Juni 29, 2023
Glioma, Society, SNMMI, Ayub Ommaya, Safety, Cohort, Cerebrospinal fluid, Plus Therapeutics, MCI, ML, Patient, Risk, LM, PSTV, Decompression (diving), CSF, Neoplasm, Toxic leukoencephalopathy, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Food, Pharmaceutical industry, Vaccine, Medical imaging, OS, Rhenium

AUSTIN, Texas, June 29, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today reported positive interim updates from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (rGBM) and leptomeningeal metastases (LM) at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting, which took place June 24-27, 2023 in Chicago, Illinois.

Key Points: 
  • A single dose of rhenium (186Re) obisbemeda was generally safe and well-tolerated, with no dose-limiting toxicities and minimal systemic radiation exposure.
  • The data demonstrates efficacy signals in a prognostically unfavorable patient population.
  • For each 10% increase in the Ratio of Treated to Total Tumor Volume, the risk of death decreases by 66.9% (p=0.002).
  • “As Phase 1 trials are designed for safety, statistically significant correlations between dose and overall survival are unusual.

ICR Hosts Plus Therapeutics CEO Marc Hedrick on the Welcome to the Arena Podcast

Retrieved on: 
Mittwoch, Juni 28, 2023
Other Communications, Public Relations, Investor Relations, Marketing, Advertising, Communications, Clinical Trials, Biotechnology, Health, Pharmaceutical, PSTV, CFOS, Radiation, Therapy, Apple Podcasts, Plus Therapeutics, ICR, Google Podcasts, Plus, Pharmaceutical industry, Spotify

ICR , a leading strategic communications and advisory firm, is pleased to announce that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, recently appeared on Episode 81 of ICR’s “Welcome to the Arena” podcast.

Key Points: 
  • ICR , a leading strategic communications and advisory firm, is pleased to announce that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, recently appeared on Episode 81 of ICR’s “Welcome to the Arena” podcast.
  • Welcome to the Arena is hosted by Tom Ryan, Co-Founder & CEO of ICR.
  • Tom spoke with Marc about the cutting-edge treatments at Plus Therapeutics, why they're different from traditional radiotherapy, and more.
  • The Welcome to the Arena podcast has featured discussions with CEOs, CFOs, financial analysts, members of the media, investment bankers, private equity executives and others who influence and create value for public and private-equity backed companies.

Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Retrieved on: 
Mittwoch, Juni 14, 2023
Plus, PSTV, Plus Therapeutics, Therapy, Conference, Pharmaceutical industry, Cryptocurrency

AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to participate in a fireside chat at the 2023 Healthcare Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, June 21, 2023 at 3:30 p.m.

Key Points: 
  • AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to participate in a fireside chat at the 2023 Healthcare Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, June 21, 2023 at 3:30 p.m.
  • ET.
  • The conference will take place June 20-22, 2023, and will be hosted live on M-Vest and available under the For Investors tab of the Plus Therapeutics website at www.plustherapeutics.com .
  • To attend virtually, sign up to become an M-Vest member here: Reserve Your Seat .

Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

Retrieved on: 
Donnerstag, Juni 8, 2023
Glioma, Society, SNMMI, SNO, Plus Therapeutics, LM, PSTV, Decompression (diving), Rhenium, Therapy, Conference, Pharmaceutical industry

AUSTIN, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.

Key Points: 
  • AUSTIN, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will exhibit at both the Society for NeuroOncology’s (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging’s (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.
  • In addition, at the SNMMI Annual Meeting, Norman LaFrance, M.D., Chief Medical Officer, will present data from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (rGBM) and leptomeningeal metastases (LM), respectively.
  • Details of SNMMI poster presentations:
    Nanoliposome) (186Re) Obisbemeda in Recurrent Glioma: The ReSPECT-GBM Trial [P988]

Plus Therapeutics Provides Company Update Today

Retrieved on: 
Donnerstag, Juni 1, 2023
PSTV, Therapy, Plus Therapeutics, Plus, Cryptocurrency

AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will provide a comprehensive update of the Company’s recent activity and progress to date during a presentation at the 2023 Virtual June Investor Summit on Thursday, June 1, 2023, at 2:00 p.m.

Key Points: 
  • AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will provide a comprehensive update of the Company’s recent activity and progress to date during a presentation at the 2023 Virtual June Investor Summit on Thursday, June 1, 2023, at 2:00 p.m.
  • The presentation will provide a comprehensive update on Plus Therapeutics’ clinical and preclinical development programs.
  • Investors interested in arranging a meeting with the Company’s management during the conference should contact the Investor Summit conference coordinator.
  • A webcast of the presentation can be found here and will be available along with an updated Company presentation under the For Investors tab of the Plus website at www.plustherapeutics.com .